Bracket acquires mProve, both committed to ‘BYOD’ in clinical trials, says CEO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/oatawa)
(Image: Getty/oatawa)

Related tags: Food and drug administration

“Bring Your Own Device” (BYOD) in clinical trials will be a “critical component” of future research says Bracket CEO following the company’s acquisition of mProve Health.

The clinical trial technology and service provider announced the acquisition of mProve Health​ yesterday. The transaction as supported by the private equity firm and Bracket owner​, Genstar Capital.

mProve has an aggressive technology roadmap and numerous new products and features due to be released in the coming months​,” Jeff Lee, CEO, mProve Health, told Outsourcing-Pharma.com

mProve Health is mobile technology​ provider offering mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments (eCOA).

mProve’s patient engagement tools are a natural complement to our existing eCOA platform. Our first priority will be working with sponsors to bring these two together​,” Jeff Kinell, CEO, Bracket told Outsroucing-Pharma.com.

Moving forward as of now mProve will operate with some independence, he explained. The companies are already working with several sponsor companies on clinical trials together, ​Kinell said.

Bracket and mProve are committed to BYOD,”​ added Kinell. “I think there is a clear consensus from stakeholders that this will be a critical component of research​ in the future​.”

Kinell explained the US Food and Drug Administration (FDA) has been especially receptive to this, ​noting that Lee from mProve has already met with the agency to discuss best practices.

“This investment is a reflection of our belief that this is an important and growing area,​” he added.

Although patient engagement is an emerging area, the data from trials that are leveraging this approach are tremendous. mProve has data showing that patient retention goes up, medication adherence is high, patient compliance with diaries is better, when comprehensive patient engagement programs are put in place​.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars